Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1998 1
1999 3
2000 3
2001 3
2002 2
2003 1
2004 4
2005 5
2006 6
2007 1
2008 6
2009 8
2010 11
2011 11
2012 11
2013 18
2014 26
2015 29
2016 44
2017 33
2018 30
2019 24
2020 25
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

266 results
Results by year
Filters applied: . Clear all
Page 1
Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.
Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA. Suthahar N, et al. Theranostics. 2018 Jan 1;8(3):593-609. doi: 10.7150/thno.22196. eCollection 2018. Theranostics. 2018. PMID: 29344292 Free PMC article. Review.
Galectin-3 is a versatile protein orchestrating several physiological and pathophysiological processes in the human body. In the last decade, considerable interest in galectin-3 has emerged because of its potential role as a biotarget. ...
Galectin-3 is a versatile protein orchestrating several physiological and pathophysiological processes in the human body. In t
Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y, Yoneda M. Sumida Y, et al. J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16. J Gastroenterol. 2018. PMID: 29247356 Free PMC article. Review.
GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects. Innovative NASH therapies include four main pathways. ...Antifibrotic agents are a cysteine-cysteine …
GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial …
Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease.
Ozkurt S, Dogan I, Ozcan O, Fidan N, Bozaci I, Yilmaz B, Bilgin M. Ozkurt S, et al. Int Urol Nephrol. 2019 Jul;51(7):1191-1197. doi: 10.1007/s11255-019-02156-8. Epub 2019 Apr 22. Int Urol Nephrol. 2019. PMID: 31012038
New treatment approaches for ADPKD have led to a need for easily applicable strong biomarkers predicting progression of the disease. The profibrotic mediator of galectin-3 (Gal-3) is linked to development of renal fibrosis. METHODS: The study included …
New treatment approaches for ADPKD have led to a need for easily applicable strong biomarkers predicting progression of the disease. The pro …
GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, de Boer I, Brosius F, Gadegbeku C, Gipson D, Hawkins J, Himmelfarb J, Ju W, Kestenbaum B, Kretzler M, Robinson-Cohen C, Steigerwalt S, Bansal N. Tuegel C, et al. Am J Kidney Dis. 2018 Oct;72(4):519-528. doi: 10.1053/j.ajkd.2018.03.025. Epub 2018 Jun 14. Am J Kidney Dis. 2018. PMID: 29866459 Free PMC article.
RATIONALE & OBJECTIVE: Inflammation, cardiac remodeling, and fibrosis may explain in part the excess risk for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Growth differentiation factor 15 (GDF-15), galectin 3 (Gal-3), …
RATIONALE & OBJECTIVE: Inflammation, cardiac remodeling, and fibrosis may explain in part the excess risk for cardiovascular disease (CV …
Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V, Markovic BS, Jankovic MG, Djokovic B, Jovicic N, Harrell CR, Fellabaum C, Djonov V, Arsenijevic N, Lukic ML. Volarevic V, et al. Theranostics. 2019 Aug 14;9(20):5976-6001. doi: 10.7150/thno.33959. eCollection 2019. Theranostics. 2019. PMID: 31534532 Free PMC article.
Galectin 3 (Gal-3), expressed on renal DCs, is known as a crucial regulator of immune response in the kidneys. ...Recombinant Gal-3 managed to completely attenuate CDDP-induced apoptosis in CDDP-injured kidneys of Gal-3(-/-)
Galectin 3 (Gal-3), expressed on renal DCs, is known as a crucial regulator of immune response in the kidneys
Acute Kidney Injury Induces Remote Cardiac Damage and Dysfunction Through the Galectin-3 Pathway.
Prud'homme M, Coutrot M, Michel T, Boutin L, Genest M, Poirier F, Launay JM, Kane B, Kinugasa S, Prakoura N, Vandermeersch S, Cohen-Solal A, Delcayre C, Samuel JL, Mehta R, Gayat E, Mebazaa A, Chadjichristos CE, Legrand M. Prud'homme M, et al. JACC Basic Transl Sci. 2019 Oct 28;4(6):717-732. doi: 10.1016/j.jacbts.2019.06.005. eCollection 2019 Oct. JACC Basic Transl Sci. 2019. PMID: 31709320 Free PMC article.
Acute kidney injury is associated with increased risk of heart failure and mortality. This study demonstrates that acute kidney injury induces remote cardiac dysfunction, damage, injury, and fibrosis via a galectin-3 (Gal-3) dependent pathway. . …
Acute kidney injury is associated with increased risk of heart failure and mortality. This study demonstrates that acute kidney
Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander.
Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Desmedt V, et al. Am J Nephrol. 2016;43(5):305-17. doi: 10.1159/000446376. Epub 2016 May 12. Am J Nephrol. 2016. PMID: 27166158 Free article. Review.
Finally, the therapeutic potential of anti-galectin-3 inhibitors is discussed. KEY MESSAGES: Due to its multifunctional character, galectin-3 plays a pivotal role in interstitial fibrosis and progression of chronic kidney disease. Inhibition of …
Finally, the therapeutic potential of anti-galectin-3 inhibitors is discussed. KEY MESSAGES: Due to its multifunctional charac …
Soluble ST2 and Galectin-3 and Progression of CKD.
Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N. Alam ML, et al. Kidney Int Rep. 2018 Sep 21;4(1):103-111. doi: 10.1016/j.ekir.2018.09.013. eCollection 2019 Jan. Kidney Int Rep. 2018. PMID: 30596173 Free PMC article.
INTRODUCTION: Cardiac biomarkers soluble ST2 (sST2) and galectin-3 may reflect cardiac inflammation and fibrosis. It is plausible that these mechanisms may also contribute to the progression of kidney disease. We examined associations of sST2 and galectin
INTRODUCTION: Cardiac biomarkers soluble ST2 (sST2) and galectin-3 may reflect cardiac inflammation and fibrosis. It is plausi …
Expression of galectin-1 and galectin-3 in renal cell carcinoma; immunohistochemical study.
Aboulhagag NA, El-Deek HEM, Sherif MF. Aboulhagag NA, et al. Ann Diagn Pathol. 2018 Oct;36:31-37. doi: 10.1016/j.anndiagpath.2018.06.005. Epub 2018 Jun 21. Ann Diagn Pathol. 2018. PMID: 30055522
This study aimed at studying the immunohistochemical expression of both galectin-1 and galectin-3 in renal cell carcinoma (RCC) variants and detecting the possible association of galectins with various clinicopathological parameters. ...RESULTS: In app …
This study aimed at studying the immunohistochemical expression of both galectin-1 and galectin-3 in renal cell …
Expression and Distribution of Galectin-3 in Chromophobe and Papillary Carcinomas.
Cioca A, Muntean D, Bungardean C, Raica M, Cimpean AM. Cioca A, et al. Anticancer Res. 2018 Jan;38(1):259-263. doi: 10.21873/anticanres.12216. Anticancer Res. 2018. PMID: 29277781
Moreover, the optimal therapy for patients with non-clear renal cell carcinoma (RCC) is unknown yet. Although elevated levels of Galectin-3 (Gal-3) were associated with poor prognosis in conventional RCC, the impact of this protein on carcinogenesis of …
Moreover, the optimal therapy for patients with non-clear renal cell carcinoma (RCC) is unknown yet. Although elevated levels of G
266 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback